ARGX-117, a therapeutic complement inhibiting antibody targeting C2

Activation of the classical and lectin pathway of complement may contribute to tissue damage and organ dysfunction of antibody-mediated diseases and ischemia-reperfusion conditions. Complement factors are being considered as targets for therapeutic intervention

Source: Journal of Allergy and Clinical Immunology - September 10, 2020 Category: Allergy & Immunology Authors: Inge Van de Walle, Karen Silence, Kevin Budding, Liesbeth Van de Ven, Kim Dijkxhoorn, Elisabeth de Zeeuw, Cafer Yildiz, Sofie Gabriels, Jean-Michel Percier, Johanna Wildemann, Jan Meeldijk, Peter J. Simons, Louis Boon, Linda Cox, Rob Holgate, Rolf Urbanus Source Type: research